NicOx Reacquires Rights to Glaucoma Drug PF-03187207 from Pfizer
Links shared publicly online about this topic.
- 1,825total visits
NicOx Reacquires Rights to Glaucoma Drug PF-03187207 from Pfizer
View full resource at eyedocnews.com
Tags: Glaucoma, Glaucoma Medication, Intraocular Pressure Medication, Drug, Xalatan, Pfizer
Most Recently Shared on August 14, 2009 at 3:39 am By:
Discuss: NicOx Reacquires Rights to Glaucoma Drug From Pfizer: By Dr. Dominique Walton BrooksThe French .. http://bit.ly/vfcGi
NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer - Ophthalmology Times Europe
oteurope.com — “NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data.” View full resource at oteurope.com
Most Recently Shared on August 20, 2009 at 1:40 pm By:
Ophthalmology Times Ophthalmology and Health Magazine
NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer. http://ow.ly/kxUx
Advertisement
